Antimicrobial resistance and infectious disease
5 European H2020 organizations list this as part of their work — 1 as their primary capability.
Most active in this area
- UNIVERSITA DEGLI STUDI DI VERONA
Italian university strong in autonomous surgical robotics, neuroinflammation research, and historical linguistics, with high project coordination capacity.
“Three recent projects with AMR keywords; COVID-19 research activity appearing in second-half keyword profile.”
IT56 projects - STICHTING LYGATURE
Dutch foundation orchestrating public-private partnerships in clinical trials, digital health, and FAIR data across European biomedical research.
“GNA NOW (coordinator, gram-negative antibiotics development) and UNITE4TB (tuberculosis treatment innovation) address critical gaps in anti-infective drug pipelines.”
SMENL19 projects - BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL
Germany's federal regulatory authority for vaccines and advanced therapies, contributing regulatory science and safety assessment expertise to European health research consortia.
“COMBINE targets MDR bacterial infections, TIPAT focuses on personalized antibiotic treatment and pharmacokinetics, and TBVAC2020 addressed tuberculosis vaccine development.”
DE15 projects - EUROPEAN RESPIRATORY SOCIETY
Europe's leading respiratory medicine society, active in AMR, AI diagnostics, and international researcher training through H2020 clinical consortia.
“VALUE-Dx, FAIR, ECRAID-Base, and UNITE4TB all address AMR, drug-resistant infections, or clinical trial infrastructure for infectious diseases.”
PrimaryCH12 projects - CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE TOURS
French university hospital contributing clinical trial sites, pharmacokinetic expertise, and patient cohorts in neuroscience, infectious disease, and regenerative medicine.
“AB-DiRecT focuses on antibiotic distribution in tissue for gonorrhoea and prostatitis, while FAIR addresses drug-resistant pneumonia through immunomodulatory aerosol therapy.”
FR7 projects